Clinical Trials Browser

Breast Neoplasms × MLN 8237 × Clear all

NCT02860000 2026-02-27

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Phase 2 Completed

96 enrolled 34 charts

Breast Neoplasms

NCT06369285 2025-12-10

ALISCA-Breast1

Phase 2 Recruiting

Breast Neoplasms

NCT02187991 2024-10-09

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

Phase 2 Completed

169 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02719691 2022-07-25

Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

Phase 1 Completed

47 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01639911 2019-07-22

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

Phase 1 Completed

BreastCNSDermatologicGastrointestinalHead & Neck

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Melanoma, Central Nervous System Neoplasms

NCT02219789 2018-10-03

Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Phase 1 Completed

Breast Neoplasms

NCT01091428 2018-06-04

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Phase 2 Completed

191 enrolled 39 charts

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01045421 2016-08-15

Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Phase 1/2 Completed

273 enrolled 28 charts

BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma